18:16 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting GM-CSF and MMP9 could help treat breast cancer in obese patients. In an obese genetic mouse model of breast cancer, white adipose tissue (WAT) levels of...
04:22 , Apr 7, 2017 |  BC Week In Review  |  Company News

Calypso, EA Pharma deal

Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001. The companies will collaborate to develop the human mAb targeting matrix metalloproteinase 9 (MMP9) to treat inflammatory bowel disease (IBD). Calypso...
07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

Ophthalmic disease INDICATION: Diabetic macular edema (DME) Patient sample and mouse studies suggest inhibiting MMP9 could help treat DME. Levels of MMP9 and a truncated form of the MMP9 substrate NTN1 were higher in vitreous humor samples...
07:00 , May 27, 2013 |  BioCentury  |  Emerging Company Profile

Calypso: Fistula fix

Calypso Biotech S.A. has mAbs against an undisclosed target to treat fistulizing Crohn's disease, a severe form of the condition that usually is refractory to marketed therapies such as immunomodulators. The company expects it will...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Calypso Biotech, iDD Biotech deal

iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002, a humanized mAb, to treat refractory celiac disease. iDD received an upfront payment and is eligible for milestones, plus royalties. CALY-002 is in preclinical development,...